Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019
April 10, 2019 16:35 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to...
Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG
April 04, 2019 16:07 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with...
Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG
March 27, 2019 06:00 ET
|
Vital Therapies, Inc.
Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals
March 25, 2019 05:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both...
Vital Therapies Announces 2018 Financial Results
March 04, 2019 16:10 ET
|
Vital Therapies, Inc.
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute...
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
January 07, 2019 04:00 ET
|
Vital Therapies, Inc.
– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an...
Vital Therapies Announces Third Quarter 2018 Financial Results
November 07, 2018 18:20 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms...
Vital Therapies Provides Strategic Update
October 11, 2018 09:27 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
Vital Therapies to Present at the 19th International Liver Support Meeting
September 29, 2018 10:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver...
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
September 12, 2018 05:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...